Cxl Ophthalmics, LLC

Other

Cornell Research Foundation Inc.

Epion Therapeutics, Inc.

Raymond A Hartman

Roy S Rubinfeld

Sandy T Feldman

Kevin E Daly

Todd K Rosengart

Ronald G Crystal

Charles A Mack, Iii

Bill Trattler

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

Ophthalmic treatment device, system, and method of use

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

Compositions and methods for treating or preventing diseases associated with oxidative stress

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.

Ocular cross-linking system and method for sealing corneal wounds

A targeted UV phototherapy apparatus has a UV radiation source for emitting UV radiation at a first wavelength and a phosphor element separate from the source for converting the UV radiation in the first wavelength to a different UV wavelength in the therapeutic UVB or UVA range. A radiation directing assembly directs radiation from the UV source to the separate phosphor element, and a shaped exit aperture placed directly against a lesion directs radiation emitted from the phosphor element onto a predetermined target area of the lesion.

Targeted UV phototherapy apparatus and method

A UV phototherapy apparatus has a base unit containing a UVB arc lamp and an output port for delivery of UVB radiation within a predetermined range. A flexible, elongate optical guide is connected to the output port at one end and to a handpiece at the opposite end. The handpiece is arranged to convert the round beam from the optical guide into a predetermined straight-edged shape such as a rectangular beam, and has an exit aperture of corresponding shape for delivering the shaped beam to a target area of a patient. A beam isolating assembly in the optical path isolates UVB radiation in the predetermined range from the lamp output, so that at least 90% of the radiation directed into the optical guide is in the predetermined range.

Apparatus and method for targeted UV phototherapy of skin disorders

The invention is directed to a device and method for delivering a therapeutic substance to a bodily tissue in a minimally invasive manner. The device includes an elongate flexible tubular member having a proximal end and a distal end. A control means is provided for enabling the distal end of the tubular member to be controllably flexed in a transverse manner for positioning the distal end of the tubular member proximate to the bodily tissue to be treated. A hollow needle is disposed at the distal end of the tubular member for delivering the therapeutic substance into the bodily tissue. A marking means is also included for indicating when a injection has been made in the tissue. The invention is particularly useful for treatment of ischemic heart disease by gene therapy.

Minimally invasive gene therapy delivery device and method

A gene transfer delivery apparatus and method includes a plurality of syringes retained in a syringe-retaining portion. Each syringe contains a predetermined quantity of treatment solution. The treatment solution may be expelled through a needle on the end of each syringe by depressing the syringe plunger associated with each syringe. The syringe-retaining portion of the delivery device is connected to a plunger portion which contains a main plunger capable of depressing the syringe plungers simultaneously. Since the syringe plungers are depressed uniformly, the delivery device allows for the precise injection of a fixed volume of fluid at plural locations and at a predetermined depth. A spring-biased platen is mounted on the device for flattening the tissue prior insertion of the needles into the tissue. A method of using the delivery device for treatment of ischemic heart disease by gene therapy is also disclosed.

Growing community of inventors

Carlsbad, CA, United States of America

Raymond A Hartman